Skip to main content
Erschienen in: Acta Diabetologica 6/2014

01.12.2014 | Original Article

TNFRSF11B gene polymorphisms increased risk of peripheral arterial occlusive disease and critical limb ischemia in patients with type 2 diabetes

verfasst von: Federico Biscetti, Carlo Filippo Porreca, Flavio Bertucci, Giuseppe Straface, Angelo Santoliquido, Paolo Tondi, Flavia Angelini, Dario Pitocco, Luca Santoro, Antonio Gasbarrini, Raffaele Landolfi, Andrea Flex

Erschienen in: Acta Diabetologica | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Aims

Osteoprotegerin (OPG) is a secretory glycoprotein that belongs to the tumor necrosis factor receptor family and plays a role in atherosclerosis. OPG has been hypothesized to modulate vascular functions; however, its role in mediating atherosclerosis is controversial. Epidemiological data in patients with cardiovascular disease (CVD) indicate that OPG serum levels are associated with several inflammatory markers, myocardial infarction events, and calcium scores, suggesting that OPG may be causative for CVD.

Methods

The present study aimed to evaluate whether the OPG gene (TNFRSF11B) polymorphisms are involved in the development of peripheral arterial occlusive disease (PAOD) and critical limb ischemia (CLI) in patients with type 2 diabetes. This genetic association study included 402 diabetic patients (139 males and 263 females) with peripheral arterial occlusive disease and 567 diabetic subjects without peripheral arterial occlusive disease (208 males and 359 females). The T245G, T950C, and G1181C polymorphisms of the OPG gene were analyzed by polymerase chain reaction and restriction fragment length polymorphism.

Results

We found that the T245G, T950C, and G1181C gene polymorphisms of the OPG gene were significantly (27.9 vs. 12.2 %, P < 0.01; 33.6 vs. 10.4 %, P < 0.01 and 24.4 vs. 12.7 %, P < 0.01, respectively) and independently (adjusted OR 4.97 (3.12–6.91), OR 7.02 (4.96–11.67), and OR 2.85 (1.95–4.02), respectively) associated with PAOD. We also found that these three polymorphisms act synergistically in patients with PAOD and are associated with different levels of risk for PAOD and CLI, depending on the number of high-risk genotypes carried concomitantly by a given individual.

Conclusion

The TNFRSF11B gene polymorphisms under study are associated with PAOD, and synergistic effects between these genotypes might be potential markers for the presence and severity of atherosclerotic disorders.
Literatur
2.
Zurück zum Zitat Marinkovic N, Pasalic D, Potocki S (2013) Polymorphisms of genes involved in polycyclic aromatic hydrocarbons’ biotransformation and atherosclerosis. Biochem Med (Zagreb) 23:255–265. doi:10.11613/BM.2013.032 CrossRef Marinkovic N, Pasalic D, Potocki S (2013) Polymorphisms of genes involved in polycyclic aromatic hydrocarbons’ biotransformation and atherosclerosis. Biochem Med (Zagreb) 23:255–265. doi:10.​11613/​BM.​2013.​032 CrossRef
3.
Zurück zum Zitat Munger MA, Hawkins DW (2004) Atherothrombosis: epidemiology, pathophysiology, and prevention. J Am Pharm Assoc 44(Suppl 1):S5–S13 Munger MA, Hawkins DW (2004) Atherothrombosis: epidemiology, pathophysiology, and prevention. J Am Pharm Assoc 44(Suppl 1):S5–S13
4.
Zurück zum Zitat Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR et al (1992) Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 326:381–386PubMedCrossRef Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR et al (1992) Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 326:381–386PubMedCrossRef
7.
Zurück zum Zitat Sesti G, Andreozzi F, Fiorentino TV, Mannino GC, Sciacqua A et al (2014) High circulating irisin levels are associated with insulin resistance and vascular atherosclerosis in a cohort of nondiabetic adult subjects. Acta Diabetol 51:705–713. doi:10.1007/s00592-014-0576-0 Sesti G, Andreozzi F, Fiorentino TV, Mannino GC, Sciacqua A et al (2014) High circulating irisin levels are associated with insulin resistance and vascular atherosclerosis in a cohort of nondiabetic adult subjects. Acta Diabetol 51:705–713. doi:10.​1007/​s00592-014-0576-0
8.
Zurück zum Zitat Jung CH, Lee WY, Kim SY, Jung JH, Rhee EJ et al (2010) The relationship between coronary artery calcification score, plasma osteoprotegerin level and arterial stiffness in asymptomatic type 2 DM. Acta Diabetol 47(Suppl 1):145–152. doi:10.1007/s00592-009-0154-z PubMedCrossRef Jung CH, Lee WY, Kim SY, Jung JH, Rhee EJ et al (2010) The relationship between coronary artery calcification score, plasma osteoprotegerin level and arterial stiffness in asymptomatic type 2 DM. Acta Diabetol 47(Suppl 1):145–152. doi:10.​1007/​s00592-009-0154-z PubMedCrossRef
11.
Zurück zum Zitat Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319PubMedCrossRef Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319PubMedCrossRef
13.
Zurück zum Zitat Dai Y, Shen L (2007) Relationships between serum osteoprotegerin, matrix metalloproteinase-2 levels and bone metabolism in postmenopausal women. Chin Med J (Engl) 120:2017–2021 Dai Y, Shen L (2007) Relationships between serum osteoprotegerin, matrix metalloproteinase-2 levels and bone metabolism in postmenopausal women. Chin Med J (Engl) 120:2017–2021
14.
Zurück zum Zitat Turk N, Cukovic-Cavka S, Korsic M, Turk Z, Vucelic B (2009) Proinflammatory cytokines and receptor activator of nuclear factor kappaB-ligand/osteoprotegerin associated with bone deterioration in patients with Crohn’s disease. Eur J Gastroenterol Hepatol 21:159–166. doi:10.1097/MEG.0b013e3283200032 PubMedCrossRef Turk N, Cukovic-Cavka S, Korsic M, Turk Z, Vucelic B (2009) Proinflammatory cytokines and receptor activator of nuclear factor kappaB-ligand/osteoprotegerin associated with bone deterioration in patients with Crohn’s disease. Eur J Gastroenterol Hepatol 21:159–166. doi:10.​1097/​MEG.​0b013e3283200032​ PubMedCrossRef
15.
Zurück zum Zitat Goranova-Marinova V, Goranov S, Tzveltkova T (2007) Serum levels of OPG, RANKL and RANKL/OPG ratio in newly-diagnosed patients with multiple myeloma. Clinical correlations. Haematologica 92:1000–1001. doi:10.3324/haematol.10943 PubMedCrossRef Goranova-Marinova V, Goranov S, Tzveltkova T (2007) Serum levels of OPG, RANKL and RANKL/OPG ratio in newly-diagnosed patients with multiple myeloma. Clinical correlations. Haematologica 92:1000–1001. doi:10.​3324/​haematol.​10943 PubMedCrossRef
17.
Zurück zum Zitat Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J et al (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260–1268PubMedCentralPubMedCrossRef Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J et al (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260–1268PubMedCentralPubMedCrossRef
18.
21.
22.
Zurück zum Zitat Straface G, Biscetti F, Pitocco D, Bertoletti G, Misuraca M et al (2011) Assessment of the genetic effects of polymorphisms in the osteoprotegerin gene, TNFRSF11B, on serum osteoprotegerin levels and carotid plaque vulnerability. Stroke 42:3022–3028. doi:10.1161/STROKEAHA.111.619288 PubMedCrossRef Straface G, Biscetti F, Pitocco D, Bertoletti G, Misuraca M et al (2011) Assessment of the genetic effects of polymorphisms in the osteoprotegerin gene, TNFRSF11B, on serum osteoprotegerin levels and carotid plaque vulnerability. Stroke 42:3022–3028. doi:10.​1161/​STROKEAHA.​111.​619288 PubMedCrossRef
23.
Zurück zum Zitat Crisafulli A, Micari A, Altavilla D, Saporito F, Sardella A (2005) Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci (Lond) 109:389–395. doi:10.1042/CS20050058 CrossRef Crisafulli A, Micari A, Altavilla D, Saporito F, Sardella A (2005) Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci (Lond) 109:389–395. doi:10.​1042/​CS20050058 CrossRef
24.
Zurück zum Zitat Rutherford RB, Flanigan DP, Gupta SK, The Ad Hoc Committee on Reporting Standards SVS, ISCVS (1986) Suggested standards for reports dealing with lower extremity ischaemia. J Vasc Surg 4:80–94CrossRef Rutherford RB, Flanigan DP, Gupta SK, The Ad Hoc Committee on Reporting Standards SVS, ISCVS (1986) Suggested standards for reports dealing with lower extremity ischaemia. J Vasc Surg 4:80–94CrossRef
25.
Zurück zum Zitat Dormandy JA, Rutherford RB (2000) Management of peripheral arterial disease (PAD). TASC working group. TransAtlantic inter-society consensus (TASC). J Vasc Surg 31:S1–S296PubMedCrossRef Dormandy JA, Rutherford RB (2000) Management of peripheral arterial disease (PAD). TASC working group. TransAtlantic inter-society consensus (TASC). J Vasc Surg 31:S1–S296PubMedCrossRef
26.
Zurück zum Zitat Biscetti F, Straface G, Giovannini S, Santoliquido A, Angelini F et al (2013) Association between TNFRSF11B gene polymorphisms and history of ischemic stroke in Italian diabetic patients. Hum Genet 132:49–55. doi:10.1007/s00439-012-1224-9 Biscetti F, Straface G, Giovannini S, Santoliquido A, Angelini F et al (2013) Association between TNFRSF11B gene polymorphisms and history of ischemic stroke in Italian diabetic patients. Hum Genet 132:49–55. doi:10.​1007/​s00439-012-1224-9
27.
Zurück zum Zitat Attia I, Thakkinstian A, D’Este C (2003) Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol 56:297–303PubMedCrossRef Attia I, Thakkinstian A, D’Este C (2003) Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol 56:297–303PubMedCrossRef
30.
Zurück zum Zitat Doherty TM, Asotra K, Fitzpatrick LA, Qiao JH, Wilkin DJ (2003) Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads. Proc Natl Acad Sci USA 10:11201–11206. doi:10.1073/pnas.1932554100 CrossRef Doherty TM, Asotra K, Fitzpatrick LA, Qiao JH, Wilkin DJ (2003) Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads. Proc Natl Acad Sci USA 10:11201–11206. doi:10.​1073/​pnas.​1932554100 CrossRef
31.
35.
Zurück zum Zitat Sangiorgi G, Rumberger JA, Severson A, Edwards WD, Gregoire J (1998) Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology. J Am Coll Cardiol 31:126–133. doi:10.1016/S0735-1097(97)00443-9 PubMedCrossRef Sangiorgi G, Rumberger JA, Severson A, Edwards WD, Gregoire J (1998) Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology. J Am Coll Cardiol 31:126–133. doi:10.​1016/​S0735-1097(97)00443-9 PubMedCrossRef
37.
Zurück zum Zitat Vliegenthart R, Oudkerk M, Song B, van der Kuip DA, Hofman A, Witteman JC (2002) Coronary calcification detected by electron-beam computed tomography and myocardial infarction. The rotterdam coronary calcification study. Eur Heart J 23:1596–1603PubMedCrossRef Vliegenthart R, Oudkerk M, Song B, van der Kuip DA, Hofman A, Witteman JC (2002) Coronary calcification detected by electron-beam computed tomography and myocardial infarction. The rotterdam coronary calcification study. Eur Heart J 23:1596–1603PubMedCrossRef
38.
Metadaten
Titel
TNFRSF11B gene polymorphisms increased risk of peripheral arterial occlusive disease and critical limb ischemia in patients with type 2 diabetes
verfasst von
Federico Biscetti
Carlo Filippo Porreca
Flavio Bertucci
Giuseppe Straface
Angelo Santoliquido
Paolo Tondi
Flavia Angelini
Dario Pitocco
Luca Santoro
Antonio Gasbarrini
Raffaele Landolfi
Andrea Flex
Publikationsdatum
01.12.2014
Verlag
Springer Milan
Erschienen in
Acta Diabetologica / Ausgabe 6/2014
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-014-0664-1

Weitere Artikel der Ausgabe 6/2014

Acta Diabetologica 6/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

RAS-Blocker bei Hyperkaliämie möglichst nicht sofort absetzen

14.05.2024 Hyperkaliämie Nachrichten

Bei ausgeprägter Nierenfunktionsstörung steigen unter der Einnahme von Renin-Angiotensin-System(RAS)-Hemmstoffen nicht selten die Serumkaliumspiegel. Was in diesem Fall zu tun ist, erklärte Prof. Jürgen Floege beim diesjährigen Allgemeinmedizin-Update-Seminar.

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

13.05.2024 Gestationsdiabetes Nachrichten

Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.